Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

BioInvent International

29,05 SEK

+7,20 %

Mindre end 1K følgere

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+7,20 %
-14,31 %
+1,04 %
-23,15 %
-24,55 %
-33,83 %
-19,75 %
-34,72 %
-96,95 %

BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Læs mere
Markedsværdi
1,91 mia. SEK
Aktieomsætning
3,78 mio. SEK
Omsætning
44,69 mio.
EBIT %
-1.054,06 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.2
2026

Årsrapport '25

29.4
2026

Delårsrapport Q1'26

29.4
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse18.11.2025, 16.04

BioStock: BioInvent receives EMA support for BI-1808

BioInvent International
Pressemeddelelse18.11.2025, 13.00

BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors

BioInvent International
Pressemeddelelse17.11.2025, 08.00

EMA Positive Opinion for Orphan Drug Designation to BioInvent’s BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma

BioInvent International

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse10.11.2025, 08.18

BioStock: BioInvent presents positive Phase I data for BI-1910

BioInvent International
Pressemeddelelse7.11.2025, 14.00

BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025

BioInvent International
Selskabsmeddelelse3.11.2025, 14.00

BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025

BioInvent International
Selskabsmeddelelse3.11.2025, 14.00

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

BioInvent International
Pressemeddelelse30.10.2025, 13.50

Redeye: BioInvent (Q3 Update) - Phase II in NSCLC up and Running

BioInvent International
Pressemeddelelse30.10.2025, 08.55

BioStock: BioInvent sharpens focus on its top clinical candidates

BioInvent International
BioInvent, Audiocast, Q3'25
Videopræsentation29.10.2025, 13.00

BioInvent, Audiocast, Q3'25

BioInvent International
Selskabsmeddelelse29.10.2025, 07.00

BioInvent International AB: Interim Report January - September 2025

BioInvent International
Pressemeddelelse27.10.2025, 14.00

Invitation to presentation of BioInvent’s Interim report January – September 2025

BioInvent International
Pressemeddelelse20.10.2025, 14.32

BioStock: BioInvent’s oncolytic virus showcased at ESMO

BioInvent International
Pressemeddelelse20.10.2025, 06.30

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

BioInvent International
Pressemeddelelse14.10.2025, 09.33

BioStock: BioInvent comments on the new chapter for BI-1206

BioInvent International
Pressemeddelelse13.10.2025, 06.30

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

BioInvent International
Pressemeddelelse8.10.2025, 06.00

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

BioInvent International
Pressemeddelelse3.10.2025, 13.00

BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC

BioInvent International
Pressemeddelelse25.9.2025, 09.52

BioStock: Video from BioInvent’s live interview at BioStock Investing in Life Science – From Seed to Success

BioInvent International
Selskabsmeddelelse2.9.2025, 08.10

BioInvent Announces Board of Directors Update

BioInvent International
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.